Evidence map›Paper›PMID 33932027›Full record

ArticleBritish journal of haematology2021

The current role of interferon in hairy cell leukaemia: clinical and molecular aspects.

Giovanni M Assanto, Costantino Riemma, Francesco Malaspina, Salvatore Perrone, Maria L De Luca, Alessandra Pucciarini, Giorgia Annechini, Gianna M D'Elia, Maurizio Martelli, Robin Foà and 2 more

Open access · hybridAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Giovanni M AssantoHaematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.ORCID 0000-0002-6190-9635
Costantino RiemmaHaematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Francesco MalaspinaHaematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Salvatore PerroneHaematology Unit, S. Maria Goretti Hospital, AUSL Latina, Latina, Italy.ORCID 0000-0001-8196-0481
Maria L De LucaHaematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Alessandra PucciariniHaematology, Department of Medicine, University and Hospital of Perugia, Perugia, Italy.
Giorgia AnnechiniHaematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Gianna M D'EliaHaematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Maurizio MartelliHaematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Robin FoàHaematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.ORCID 0000-0002-5021-3026
Enrico TiacciHaematology, Department of Medicine, University and Hospital of Perugia, Perugia, Italy.
Alessandro PulsoniHaematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Sapienza University of Rome · ITUniversity of Perugia · ITCentro di Riferimento Oncologico della Basilicata · ITOspedale Santa Maria Goretti · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the current role of interferon-alpha (IFNα) in hairy cell leukaemia (HCL) in a retrospective analysis of patients with HCL. A cohort of 74 patients with HCL was divided in to three groups: (A) patients aged >65 years with first-line treatment; (B) patients with comorbidities with first-line treatment; (C) patients who were purine analogues resistant. In total, 94% achieved a response, with a complete response rate of 24%. After a median (range) follow-up of 60 (7-236) months, 55 patients (78%) are still responding. The 5-year progression-free survival was 95%, 68%, and 96% in groups A, B and C respectively. A proportion of patients were monitored through their B-Raf proto-oncogene, serine/threonine kinase (BRAF)-V600E status. IFNα remains a possible option in select patients with HCL, where minimal residual disease negativity is achievable.

Indexed as

AdultAgedAged, 80 and overAlopeciaAntineoplastic AgentsBiomarkers, TumorComorbidityDisease-Free SurvivalDrug Resistance, NeoplasmDrug SubstitutionFemaleFollow-Up StudiesHumansInterferon-alphaKaplan-Meier EstimateLeukemia, Hairy CellAntineoplastic AgentsBiomarkers, TumorBRAF protein, humanInterferon-alphaProto-Oncogene Proteins B-rafBRAFHairy cell leukaemiainterferonlymphoproliferative diseaseMRD

Identifiers

PMID33932027
PMCPMC8360059
OpenAlexW3159074124

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.